Skip to content
Colorectal Cancer Clinical Trials

Durham, North Carolina

Colorectal cancer clinical trials in Durham, NC

38 colorectal cancer studies are recruiting participants at sites in Durham as of November 16, 2026, according to ClinicalTrials.gov. Colorectal Cancer Clinical Trials can help you understand your options and connect with a study team.

Call (888) 385-9581
  • No cost to ask
  • Taking part is voluntary
  • Studies are independently reviewed

Durham at a glance

  • 38 studies are recruiting at a site in Durham.
  • By phase: Phase 1 (12), Phase 1/2 (9), Phase 2 (3), Phase 2/3 (1), Phase 3 (5), No phase (6), Observational (2). Studies of devices and behavioral approaches have no phase.
  • By sponsor: industry (29), university, hospital or other (8), government (1).
  • Most recent update to one of these records: November 16, 2026.

Studies recruiting in Durham

Basic details from each study's public record (the 30 most recently updated of 38). Select a study to read the full record on ClinicalTrials.gov, including how to contact its team.

  1. Testing Pump Chemotherapy in Addition to Standard of Care Chemotherapy Versus Standard of Care Chemotherapy Alone for Patients With Unresectable Colorectal Liver Metastases: The PUMP Trial

    • Phase 3
    • Ages 18 and older
    • All sexes
    Sponsor
    ECOG-ACRIN Cancer Research Group
    Study site
    Duke University Medical Center
    Registry record
    NCT05863195 · updated
  2. A Study of ASP546C in Adults With Gastroesophageal Cancer, Pancreatic Cancer or Other Solid Tumors

    • Phase 1/2
    • Ages 18 and older
    • All sexes
    Sponsor
    Astellas Pharma Global Development, Inc.
    Study site
    Duke Cancer Center Durham
    Registry record
    NCT07488676 · updated
  3. The Vanguard Study: Testing a New Way to Screen for Cancer

    • No phase
    • Ages 45 to 75
    • All sexes
    Sponsor
    National Cancer Institute (NCI)
    Study site
    Durham VA Medical Center
    Registry record
    NCT06995898 · updated
  4. Five or Ten Year Colonoscopy for 1-2 Non-Advanced Adenomatous Polyps

    • No phase
    • Ages 45 to 70
    • All sexes
    Sponsor
    NRG Oncology
    Study site
    Durham VA Medical Center
    Registry record
    NCT05080673 · updated
  5. Colon Adjuvant Chemotherapy Based on Evaluation of Residual Disease

    • Phase 2/3
    • Ages 18 and older
    • All sexes
    Sponsor
    NRG Oncology
    Study site
    Duke University Medical Center
    Registry record
    NCT05174169 · updated
  6. Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection

    • Observational
    • Ages 40 to 75
    • All sexes
    Sponsor
    Alliance for Clinical Trials in Oncology
    Study site
    Durham VA Medical Center
    Registry record
    NCT05334069 · updated
  7. A Study of LY4337713 in Participants With FAP-Positive Solid Tumors

    • Phase 1
    • Ages 18 and older
    • All sexes
    Sponsor
    Eli Lilly and Company
    Study site
    Duke University Medical Center
    Registry record
    NCT07213791 · updated
  8. Phase 1 Study Evaluating the Safety and PK of ADU-1805 in Advanced Solid Tumors

    • Phase 1
    • Ages 18 and older
    • All sexes
    Sponsor
    Sairopa B.V.
    Study site
    Duke Health - Duke University Hospital
    Registry record
    NCT05856981 · updated
  9. A Study to Learn About Study Medicine ALTA3263 in Adults With Advanced Solid Tumors With KRAS Mutations

    • Phase 1
    • Ages 18 and older
    • All sexes
    Sponsor
    Alterome Therapeutics, Inc.
    Registry record
    NCT06835569 · updated
  10. A Study to Test the Safety and Effectiveness of GSK5764227, Alone or With Other Treatments, in Participants With Advanced Gastrointestinal Cancers That Cannot be Surgically Removed (EMBOLD PanGI-201)

    • Phase 1/2
    • Ages 18 and older
    • All sexes
    Sponsor
    GlaxoSmithKline
    Study site
    GSK Investigational Site
    Registry record
    NCT06885034 · updated
  11. A Study to Access Intravenous (IV) Telisotuzumab Adizutecan in Combination With IV Bevacizumab Compared to Standard of Care IV Bevacizumabin Combination With Oral Trifluridine and Tipiracil in Adult Participants With Refractory Metastatic Colorectal Cancer

    • Phase 3
    • Ages 18 and older
    • All sexes
    Sponsor
    AbbVie
    Study site
    Duke University Medical Center /ID# 279322
    Registry record
    NCT07525206 · updated
  12. Phase 1/2 Trial of S241656 in Selected RAS/MAPK Mutation- Positive Malignancies

    • Phase 1/2
    • Ages 18 and older
    • All sexes
    Sponsor
    Institut de Recherches Internationales Servier
    Study site
    Duke University School of Medicine
    Registry record
    NCT05786924 · updated
  13. A Study to Assess Adverse Events and Change in Disease Activity in Adult Participants Receiving Intravenously Infused Telisotuzumab Adizutecan Alone or With Standard of Care in Participants With Post Adjuvant Circulating Tumor DNA Positive Colorectal Cancer and No Radiographic Evidence of Disease

    • Phase 2
    • Ages 18 and older
    • All sexes
    Sponsor
    AbbVie
    Study site
    Duke University Medical Center /ID# 279457
    Registry record
    NCT07023289 · updated
  14. Symbiotic-GI-03: A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Metastatic Colorectal Cancer

    • Phase 3
    • Ages 18 and older
    • All sexes
    Sponsor
    Pfizer
    Study sites
    Duke Cancer Center · Duke Cancer Center - Investigational Chemotherapy Service · Duke University Hospital - Vascular Interventional Radiology
    Registry record
    NCT07222800 · updated
  15. FOG-001 in Locally Advanced or Metastatic Solid Tumors

    • Phase 1/2
    • Ages 18 and older
    • All sexes
    Sponsor
    Parabilis Medicines, Inc.
    Study site
    Duke University
    Registry record
    NCT05919264 · updated
  16. The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)

    • Phase 1/2
    • Ages 12 and older
    • All sexes
    Sponsor
    PMV Pharmaceuticals, Inc
    Study site
    Duke University
    Registry record
    NCT04585750 · updated
  17. Study of Zanzalintinib in Combination With Immuno-Oncology or Other Agents in Participants With Solid Tumors

    • Phase 1
    • Ages 18 and older
    • All sexes
    Sponsor
    Exelixis
    Study site
    Exelixis Clinical Site #12
    Registry record
    NCT05176483 · updated
  18. A Study of PHN-012 in Patients With Advanced Solid Tumors

    • Phase 1
    • Ages 18 and older
    • All sexes
    Sponsor
    Pheon Therapeutics
    Study site
    PHN-012-001 Site
    Registry record
    NCT07127874 · updated
  19. Spevatamig (PT886) as Monotherapy or in Combination With Chemo and/or Targeted Therapy and/or ICI, for the Treatment of Patients With Advanced Gastrointestinal Cancers, Including Gastric, Gastroesophageal Junction, Pancreatic Ductal or Biliary Tract Carcinomas (the TWINPEAK Study)

    • Phase 1/2
    • Ages 18 and older
    • All sexes
    Sponsor
    Phanes Therapeutics
    Study site
    Duke Cancer Center
    Registry record
    NCT05482893 · updated
  20. DESTINY-PANTUMOUR04

    • Observational
    • Ages 18 to 130
    • All sexes
    Sponsor
    AstraZeneca
    Registry record
    NCT07124000 · updated
  21. Study of RAS(ON) Inhibitors in Patients With Gastrointestinal Solid Tumors

    • Phase 1/2
    • Ages 18 and older
    • All sexes
    Sponsor
    Revolution Medicines, Inc.
    Study site
    Duke University Medical Center
    Registry record
    NCT06445062 · updated
  22. A Study Evaluating the Safety, Efficacy, and Pharmacokinetics (PK) of EVOLVE104 in Participants With Advanced Urothelial and Squamous Cell Carcinomas

    • Phase 1
    • Ages 18 and older
    • All sexes
    Sponsor
    EvolveImmune United, Inc
    Study site
    Duke University Medical Center - Duke Cancer Center
    Registry record
    NCT07217171 · updated
  23. Safety of HRX215 in Patients After Minor and Major Liver Resection

    • Phase 1/2
    • Ages 18 to 75
    • All sexes
    Sponsor
    HepaRegeniX GmbH
    Study site
    Duke Cancer Institute
    Registry record
    NCT06638502 · updated
  24. A Phase 1/1b Study of IAM1363 in HER2 Cancers

    • Phase 1
    • Ages 18 and older
    • All sexes
    Sponsor
    Iambic Therapeutics, Inc
    Study site
    Duke Cancer Institute
    Registry record
    NCT06253871 · updated
  25. Study of Sotorasib, Panitumumab and FOLFIRI Versus FOLFIRI With or Without Bevacizumab-awwb in Treatment-naïve Participants With Metastatic Colorectal Cancer With KRAS p.G12C Mutation

    • Phase 3
    • Ages 18 and older
    • All sexes
    Sponsor
    Amgen
    Study site
    Duke Cancer Center
    Registry record
    NCT06252649 · updated
  26. Post-Market Study of the Signia Circular Stapler With Tri-Staple Technology in Left-sided Colon, Sigmoid, and Rectal Resections

    • No phase
    • Ages 18 and older
    • All sexes
    Sponsor
    Medtronic - MITG
    Study site
    Duke University
    Registry record
    NCT07351071 · updated
  27. A Study to Test DSP107 in Combination With Atezolizumab in Comparison With Fruquintinib as a New Treatment for Colorectal Cancer.

    • Phase 2
    • Ages 18 and older
    • All sexes
    Sponsor
    Kahr Bio Australia Pty Ltd
    Study site
    Duke University Medical Center - Duke Cancer Center
    Registry record
    NCT07235293 · updated
  28. Study of XmAb®819 in Subjects With Advanced Clear Cell Renal Cell Carcinoma

    • Phase 1
    • Ages 18 and older
    • All sexes
    Sponsor
    Xencor, Inc.
    Study site
    Xencor Investigative Site
    Registry record
    NCT05433142 · updated
  29. AMG 410 Alone and in Combination With Other Agents in Participants With KRAS Altered Advanced or Metastatic Solid Tumors

    • Phase 1
    • Ages 18 and older
    • All sexes
    Sponsor
    Amgen
    Study site
    Duke Cancer Center
    Registry record
    NCT07094113 · updated
  30. Safely Optimizing Body Weight With Mifomelatide (TCMCB07) in Patients With Newly Diagnosed Colorectal Cancer (CRC) or Pancreatic Ductal Adenocarcinoma (PDAC) Undergoing Chemotherapy

    • Phase 2
    • Ages 18 and older
    • All sexes
    Sponsor
    Endevica Bio
    Study site
    Duke University Medical Center
    Registry record
    NCT06937177 · updated

Source: ClinicalTrials.gov. Data processed . See every colorectal cancer study recruiting in Durham, NC on ClinicalTrials.gov.

Ask about studies near Durham

Tell us what you are looking for and a coordinator will contact you to talk through your options. Asking does not commit you to anything.

How should we reach you?
Add a message or the best time to reach you (optional)

Please do not include detailed medical information.

Before you contact a study

About these listings

These listings come from ClinicalTrials.gov, the study registry run by the U.S. National Library of Medicine. The data were processed on November 16, 2026. We show part of each public record (its title, phase, sponsor, basic eligibility and sites in this area) exactly as registered, and we group studies by place. Nothing in a record is reworded.

Colorectal Cancer Clinical Trials does not run these studies and is not affiliated with their sponsors. A listing is not a recommendation, and only a study's own team can tell you whether you may be eligible. Follow the link on any study to read its full record and contact that team directly, or ask us and a coordinator will help you understand your options. How we source and check what we publish.

Sources and further reading

Ask about a study

A coordinator will contact you. Asking does not commit you to anything.

Call (888) 385-9581

or send a short form

How should we reach you?

Call